Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.59 |
| ▸ | FLT4 | P35916 | 6/20 | 0.52 |
| ▸ | JAK1 | P23458 | 4/20 | 0.52 |
| ▸ | JAK3 | P52333 | 3/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 3/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | MERTK | Q12866 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3779618 | 1.00 | KDR (0.59) | KDRAURKBFLT4JAK1JAK3 | |
| SCHEMBL3779434 | 0.88 | KDR (0.73) | KDRAURKBFLT4JAK1JAK3 | |
| SCHEMBL3773825 | 0.88 | KDR (0.73) | KDRAURKBFLT4JAK1JAK3 | |
| SCHEMBL3772297 | 0.86 | AURKB (0.78) | KDRAURKBJAK1JAK3AURKA | |
| SCHEMBL3769576 | 0.86 | AURKB (0.78) | KDRAURKBJAK1JAK3AURKA | |
| SCHEMBL1703468 | 0.80 | AURKB (0.58) | KDRAURKBJAK1JAK3AURKA | |
| SCHEMBL3585653 | 0.80 | SYK (0.49) | KDRAURKBJAK1JAK3JAK2 | |
| SCHEMBL4281514 | 0.78 | AURKB (0.54) | KDRAURKBJAK3AURKAJAK2 | |
| SCHEMBL578664 | 0.78 | AURKB (0.54) | KDRAURKBJAK3AURKAJAK2 | |
| SCHEMBL18604506 | 0.75 | AURKA (0.75) | KDRAURKBJAK1JAK3AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426408-B2 | Pyrimidine inhibitors of kinases | ABBVIE INC. (US) | 2013-04-23 | — | — | US | claimed |
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | US | claimed |
| US-8426408-B2 | Pyrimidine inhibitors of kinases | ABBVIE INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | AURKA, AURKC, AURKB | KDR 38/4885AURKB 3/4885FLT4 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.